Agenus Advances Portfolio with 6 Clinical Collaborations investor.agenusbio.com/news-releases/…

My long time-time colleagues Michael Atkins (Georgetown Lombardi) & Professor Georgina Long AO (Bluesky @gvlongphdmd) (MIA) will be giving 2 of 4 Plenary Abstracts this weekend at ASCO. Michael is presenting melanoma data on DREAMseq IO vs BRAF/MEK sequencing, and Georgina updates on Rela+Nivo vs Nivo! Stay Tuned!

Beyond excited to announce 3 new clinical collaborations with @targovax, Oxford BioTherapeutics & ImmunoGenesis. These partnerships offer combo's that may unlock the power of immunotherapy more broadly & potentially offer promising benefit to patients with treatment resistant solid tumors.

Excited to share that @Jenniferbuell, CEO at MiNK Therapeutics, has been named #15 on Fast Company & @Lesbiantech’s Annual #FCQueer50 list! Jen inspires me each day as we work side by side in our fight against cancer by harnessing the power of the immune system! Congratulations!

Agenus’ CEO Garo Armen and CMO Steven O'Day, MD participated in a fireside chat at last week’s Jefferies Healthcare Conference in New York City. Listen in here: investor.agenusbio.com/events/event-d…

Excited to join the Agenus Webcast on ESMO GI data. We will be hosting this webcast on June 29th at 10 AM ET following our presentation of clinical data on botensilimab in MSS #colorectalcancer at @ESMOWorldGI. Stay tuned for registration info! #WCGIC2022

Less than a week away from @ESMOWorldGI in Barcelona! Anthony El-Khoueiry will be sharing clinical data on botensilimab & balstilimab in MSS CRC in a late-breaking oral session on June 29th. #WCGIC2022. More info at: investor.agenusbio.com/news-releases/…

Just moments away from Anthony El-Khoueiry‘s ESMO GI opening session presentation of Botensilimab in MSS CRC! Agenus #WCGIC2022 Manuel Hidalgo 🇪🇸 🇺🇸

Remarkable and unprecedented efficacy with Bot/bal combination in very IO cold advanced MSS CRC! #WCGIC2022

To hear a deeper dive of the remarkable data and implications for the path forward, join Anthony El-Khoueiry , Manuel Hidalgo 🇪🇸 🇺🇸, Heinz-Josef Lenz and myself today at 10am EST for our post-presentation webcast. #ESMOGI investor.agenusbio.com/events/event-d…

We are proud to announce that the first patient has been dosed in the Phase 1 study of AGEN1571, our wholly owned ILT2 antibody. AGEN1571 is part of our growing portfolio of clinical assets that are designed to broaden the promise of cancer immunotherapy. agenusbio.com/publications/

Agenus is pleased to announce the launch of our newly redesigned website. Follow us this week as we showcase some of its features!

I am looking forward to our #botensilimab oral presentation and the exciting Agenus event to follow

Join us today as Agenus' Senior Director, Head of Drug Discovery, Dhan Chand speaks today on the topic of Enhanced CTLA-4 Blockade alongside fellow industry leaders, and SITC series co-chairs James P. Allison and Alan J. Korman. sitcancer.org/education/webi…

We are excited to announce the grand opening of our new fully integrated manufacturing facility at Emeryville, CA on January 17th. Stay tuned for more!

Larry is center stage preparing for the Agenus opening of the state of the art commercial manufacturing facility!

WOW! Anthony El-Khoueiry presents BOTENSILMAB and survival in patients with MSS CRC! #GI23 ASCO Agenus MiNK Therapeutics

#TheLegend ⁦Anthony El-Khoueiry⁩ #GI23 Botensilimab in MSS CRC median overall survival NOT reached!. Pathbreaking. ⁦Agenus⁩ ⁦MiNK Therapeutics⁩

ICYMI: We are encouraged our phase 1a/1b study of #botensilimab (novel innate/ adaptive immune activator) + balstilimab (anti-PD-1-antibody) shows promise in heavily pretreated patients with #MSSCRC. #GI23

Our CMO Steven O'Day, MD, reflects on #ColorectalCancerAwarenessMonth, recent #news for #botensilimab in #OvarianCancer, and our mission to develop an arsenal of #immunotherapy treatments. #ColorectalCancer #oncology linkedin.com/posts/steven-o…